ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1421
CHEMBL1421
Compound Name DASATINIB
ChEMBL Synonyms SPRYCEL | BMS-354825-03 | DASATINIB | BMS-354825
Max Phase 4 (Approved)
Trade Names DASATINIB | SPRYCEL
Molecular Formula C22H26ClN7O2S

Additional synonyms for CHEMBL1421 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES Cc1nc(Nc2ncc(s2)C(=O)Nc3c(C)cccc3Cl)cc(n1)N4CCN(CCO)CC4
Standard InChI InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-1 ...
Download InChI
Standard InChI Key ZBNZXTGUTAYRHI-UHFFFAOYSA-N

Sources

  • AstraZeneca Deposited Data
  • British National Formulary
  • Orange Book
  • PubChem BioAssays
  • Sanger Institute Genomics of Drug Sensitivity in Cancer
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL1421

Molecule Features

CHEMBL1421 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:Y Chirality:Achiral Molecule Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Ephrin type-A receptor 2 inhibitor Ephrin type-A receptor 2 DailyMed
Platelet-derived growth factor receptor beta inhibitor Platelet-derived growth factor receptor beta DailyMed
SRC inhibitor SRC DailyMed
Stem cell growth factor receptor inhibitor Stem cell growth factor receptor DailyMed
Tyrosine-protein kinase ABL inhibitor Tyrosine-protein kinase ABL DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Carcinoma, Squamous CellD002294EFO:0000708squamous cell lung carcinoma2ClinicalTrials
CholangiocarcinomaD018281EFO:0005221cholangiocarcinoma2ClinicalTrials
Leukemia, Hairy CellD007943EFO:1000956hairy cell leukemia1ClinicalTrials
Leukemia, LymphoidD007945EFO:0004289lymphoid leukemia2ClinicalTrials
Lymphoma, B-Cell, Marginal ZoneD018442EFO:0000191MALT lymphoma1ClinicalTrials
Lymphoma, Non-HodgkinD008228EFO:0005952non-Hodgkins lymphoma1ClinicalTrials
PinealomaD010871EFO:1000475Pineoblastoma2ClinicalTrials
Polycythemia VeraD011087EFO:0002429polycythemia vera2ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-LymphomaD054198EFO:0000220acute lymphoblastic leukemia4ClinicalTrials
DailyMed
DailyMed
Burkitt LymphomaD002051EFO:0000309Burkitts lymphoma1ClinicalTrials
GliosarcomaD018316EFO:1001465gliosarcoma2ClinicalTrials
Idiopathic Pulmonary FibrosisD054990EFO:0000768idiopathic pulmonary fibrosis1ClinicalTrials
Leukemia, Myeloid, AcuteD015470EFO:0000222acute myeloid leukemia3ClinicalTrials
Lymphoma, Large B-Cell, DiffuseD016403EFO:0000403diffuse large B-cell lymphoma2ClinicalTrials
NeoplasmsD009369EFO:0000311cancer4ClinicalTrials
Carcinoma, Non-Small-Cell LungD002289EFO:0003060non-small cell lung carcinoma2ClinicalTrials
Lung NeoplasmsD008175EFO:0001071lung carcinoma2ClinicalTrials
Lymphoma, Large-Cell, AnaplasticD017728EFO:0003032anaplastic large cell lymphoma1ClinicalTrials
Lymphoma, Mantle-CellD020522EFO:1001469Mantle cell lymphoma1ClinicalTrials
MelanomaD008545EFO:0000756melanoma2ClinicalTrials
Mycosis FungoidesD009182EFO:1001051mycosis fungoides1ClinicalTrials
NeoplasmsD009369EFO:0000616neoplasm4ATC
ClinicalTrials
Breast NeoplasmsD001943EFO:0003869breast neoplasm2ClinicalTrials
Endometrial NeoplasmsD016889EFO:0004230endometrial neoplasm0ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-CellD015451EFO:0000095chronic lymphocytic leukemia2ClinicalTrials
LymphomaD008223EFO:0000574lymphoma2ClinicalTrials
MelanomaD008545EFO:0002617metastatic melanoma2ClinicalTrials
MesotheliomaD008654EFO:0000770malignant pleural mesothelioma2ClinicalTrials
Multiple MyelomaD009101EFO:0001378multiple myeloma2ClinicalTrials
Myelodysplastic SyndromesD009190EFO:0000198myelodysplastic syndrome1ClinicalTrials
Sezary SyndromeD012751EFO:1000785Sezary's disease1ClinicalTrials
Waldenstrom MacroglobulinemiaD008258EFO:0002616macroglobulinemia1ClinicalTrials
Carcinoma, Squamous CellD002294EFO:0000181head and neck squamous cell carcinoma2ClinicalTrials
GliomaD005910EFO:0000326central nervous system cancer2ClinicalTrials
Head and Neck NeoplasmsD006258EFO:0006859head and neck malignant neoplasia1ClinicalTrials
Immunoblastic LymphadenopathyD007119EFO:0000255angioimmunoblastic T-cell lymphoma1ClinicalTrials
Scleroderma, LocalizedD012594EFO:1001993scleroderma1ClinicalTrials
Gastrointestinal Stromal TumorsD046152Orphanet:44890Gastrointestinal stromal tumor2ClinicalTrials
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveD015464EFO:0000339chronic myelogenous leukemia3ClinicalTrials
MelanomaD008545EFO:0000389cutaneous melanoma2ClinicalTrials
NeuroblastomaD009447EFO:0000621neuroblastoma2ClinicalTrials
Pancreatic NeoplasmsD010190EFO:0002618pancreatic carcinoma2ClinicalTrials
Prostatic NeoplasmsD011471EFO:0000196metastatic prostate cancer3ClinicalTrials
Renal Insufficiency, ChronicD051436EFO:0003884chronic kidney disease2ClinicalTrials
Small Cell Lung CarcinomaD055752EFO:0000702small cell lung carcinoma2ClinicalTrials
Breast NeoplasmsD001943EFO:0000305breast carcinoma2ClinicalTrials
Prostatic NeoplasmsD011471EFO:0000673prostate adenocarcinoma3ClinicalTrials
RhabdomyosarcomaD012208EFO:0002918rhabdomyosarcoma1ClinicalTrials
Carcinoma, HepatocellularD006528EFO:0000182hepatocellular carcinoma2ClinicalTrials
Colorectal NeoplasmsD015179EFO:1001951colorectal carcinoma1ClinicalTrials
GlioblastomaD005909EFO:0000519glioblastoma multiforme2ClinicalTrials
Hematologic DiseasesD006402HP:0001871abnormality of blood and blood-forming tissues2ClinicalTrials
Hodgkin DiseaseD006689EFO:0000183Hodgkins lymphoma1ClinicalTrials
LeukemiaD007938EFO:0000565leukemia3ClinicalTrials
Lymphoma, T-Cell, PeripheralD016411EFO:0000211unspecified peripheral T-cell lymphoma1ClinicalTrials
MesotheliomaD008654EFO:0000588mesothelioma2ClinicalTrials
Prostatic NeoplasmsD011471EFO:0001663prostate carcinoma3ClinicalTrials

Clinical Data

ClinicalTrials.gov DASATINIB
The Cochrane Collaboration DASATINIB

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL1421. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL258 Tyrosine-protein kinase LCK Homo sapiens 1.000
CHEMBL1841 Tyrosine-protein kinase FYN Homo sapiens 1.000
CHEMBL3905 Tyrosine-protein kinase Lyn Homo sapiens 1.000
CHEMBL2073 Tyrosine-protein kinase YES Homo sapiens 1.000
CHEMBL4454 Tyrosine-protein kinase FGR Homo sapiens 1.000
CHEMBL267 Tyrosine-protein kinase SRC Homo sapiens 1.000
CHEMBL5319 Epithelial discoidin domain-containing receptor 1 Homo sapiens 0.996
CHEMBL4014 Tyrosine-protein kinase ABL2 Homo sapiens 0.994
CHEMBL3961 MAP kinase p38 beta Homo sapiens 0.991
CHEMBL1974 Tyrosine-protein kinase receptor FLT3 Homo sapiens 0.991
CHEMBL2480 Tyrosine-protein kinase LCK Mus musculus 0.987
CHEMBL4948 Dual specificity mitogen-activated protein kinase kinase 5 Homo sapiens 0.893
CHEMBL5122 Discoidin domain-containing receptor 2 Homo sapiens 0.885
CHEMBL4722 Serine/threonine-protein kinase Aurora-A Homo sapiens 0.878
CHEMBL2250 Tyrosine-protein kinase BLK Homo sapiens 0.858
CHEMBL3055 Cyclin-dependent kinase 7 Homo sapiens 0.801
CHEMBL4223 Tyrosine-protein kinase FRK Homo sapiens 0.542
CHEMBL6191 SPS1/STE20-related protein kinase YSK4 Homo sapiens 0.384
CHEMBL4202 Serine/threonine-protein kinase 2 Homo sapiens 0.381
CHEMBL279 Vascular endothelial growth factor receptor 2 Homo sapiens 0.281



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL258 Tyrosine-protein kinase LCK Homo sapiens 1.000
CHEMBL1841 Tyrosine-protein kinase FYN Homo sapiens 1.000
CHEMBL4454 Tyrosine-protein kinase FGR Homo sapiens 1.000
CHEMBL3905 Tyrosine-protein kinase Lyn Homo sapiens 1.000
CHEMBL2073 Tyrosine-protein kinase YES Homo sapiens 1.000
CHEMBL2480 Tyrosine-protein kinase LCK Mus musculus 0.998
CHEMBL4954 Ephrin type-A receptor 3 Homo sapiens 0.997
CHEMBL5319 Epithelial discoidin domain-containing receptor 1 Homo sapiens 0.997
CHEMBL4527 TRAF2- and NCK-interacting kinase Homo sapiens 0.997
CHEMBL3981 Serine/threonine-protein kinase 10 Homo sapiens 0.997
CHEMBL1974 Tyrosine-protein kinase receptor FLT3 Homo sapiens 0.994
CHEMBL4014 Tyrosine-protein kinase ABL2 Homo sapiens 0.991
CHEMBL267 Tyrosine-protein kinase SRC Homo sapiens 0.990
CHEMBL4223 Tyrosine-protein kinase FRK Homo sapiens 0.989
CHEMBL2250 Tyrosine-protein kinase BLK Homo sapiens 0.983
CHEMBL3834 Tyrosine-protein kinase BMX Homo sapiens 0.964
CHEMBL3886 Mixed lineage kinase 7 Homo sapiens 0.953
CHEMBL5358 Eukaryotic translation initiation factor 2-alpha kinase 4 Homo sapiens 0.943
CHEMBL3961 MAP kinase p38 beta Homo sapiens 0.936
CHEMBL5122 Discoidin domain-containing receptor 2 Homo sapiens 0.918

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
488 487.1557 3.31 7 106.51 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
9 3 0 9 3 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
10.94 7.29 .14 -.27 3 33 0.47

Structural Alerts

There are 1 structural alerts for CHEMBL1421. To view alerts please click here.

Compound Cross References

ATC L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 - ANTINEOPLASTIC AGENTS
L01X - OTHER ANTINEOPLASTIC AGENTS
L01XE - Protein kinase inhibitors
L01XE06 - dasatinib

ChemSpider ChemSpider:ZBNZXTGUTAYRHI-UHFFFAOYSA-N
DailyMed dasatinib
PubChem SID: 103905543 SID: 124893650 SID: 124893651 SID: 124893652 SID: 144206289 SID: 164339436 SID: 170465390 SID: 50100097 SID: 50125840
Wikipedia Dasatinib

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL1421



ACToR 302962-49-8
Atlas Dasatinib
BindingDB 13216
Brenda 5015
ChEBI 49375
ChemicalBook CB4506696
DrugBank DB01254
DrugCentral 785
eMolecules 10748986
EPA CompTox Dashboard DTXSID4040979
FDA SRS X78UG0A0RN
Guide to Pharmacology 5678
Human Metabolome Database HMDB0015384
IBM Patent System 2A233410D01335F80851E95146718561
LINCS LSM-1020
MolPort MolPort-003-846-143
Nikkaji J2.086.852J
PDBe 1N1
PharmGKB PA162372878
PubChem 3062316
PubChem: Drugs of the Future 12015788
PubChem: Thomson Pharma 14859389
Selleck Dasatinib
SureChEMBL SCHEMBL8226
ZINC ZINC000003986735

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/ZBNZXTGUTAYRHI-UHFFFAOYSA-N spacer
spacer